TB Biosciences, a life sciences firm commercialising tuberculosis detection kits, receives $1.5m in series A funding.
Life sciences firm TB Biosciences (TBB), which is commercialising tuberculosis detection kits developed at the New York University (NYU) School of Medicine, has received $1.5m in series A backing. NYU Innovation Venture Fund participated in the round, which was led by venture firm Originate Ventures. The funding adds to National Institute of Health funding, bringing…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
